肿瘤靶向药物治疗EGFR突变型非小细胞肺癌的临床效果研究

Clinical Effect Research of Tumor-targeted Drug Therapy for EGFR Mutant Non-small Cell Lung Cancer

探讨肿瘤靶向药物治疗表皮生长因子受体(EGFR)突变型非小细胞肺癌的临床效果。选取44例在我院治疗的EGFR突变型非小细胞肺癌患者,分为试验组和参照组,对比两组的临床疗效及不良反应发生率。结果表明:试验组的临床疗效显著优于参照组(P<0.05);不良反应发生率与参照组相比差异不显著,无统计学意义(P>0.05)。肿瘤靶向药物治疗EGFR突变型非小细胞肺癌的临床效果确切,可有效抑制肿瘤进展,具有较高的用药安全性。

The research explores the clinical effect of tumor-targeted drug therapy for EGFR mutant non-small cell lung cancer.44 patients with EGFR mutant non-small cell lung cancer in the hospital are selected,and they are divided into experimental group and control group.Clinical effect and adverse reaction rate of two groups are compared.The results show that clinical effect of experimental group is better than control group(P<0.05).There is no statistically significant difference in adverse reaction rate between two groups(P>0.05).There is exact effect of tumor-targeted drug therapy for EGFR mutant non-small cell lung cancer.It can effectively inhibit tumor progression,with higher medication safety.